PA 21
| Code | Size | Price |
|---|
| TAR-T33856-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T33856-50mg | 50mg | £1,661.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T33856-100mg | 100mg | £2,079.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
PA 21 is an iron-based noncalcium phosphate binder that prevents vascular calcification in chronic renal failure rats.
CAS:
125200-63-7
Formula:
C9H15O6P
Molecular Weight:
250.188
Purity:
0.98
SMILES:
[O-]P([O-])(=O)OCCCCCCOC(=O)C=C
References
Xie D, Ye N, Li M. A systematic review on the efficacy and safety of PA21 versus sevelamer in dialysis patients. Int Urol Nephrol. 2018 May;50(5):905-909. doi: 10.1007/s11255-017-1774-9. Epub 2018 Jan 2. Review. PubMed PMID: 29294216.
Koiwa F, Terao A. Dose-response efficacy and safety of PA21 in Japanese hemodialysis patients with hyperphosphatemia: a randomized, placebo-controlled, double-blind, Phase II study. Clin Exp Nephrol. 2017 Jun;21(3):513-522. doi: 10.1007/s10157-016-1299-z. Epub 2016 Jul 7. Erratum in: Clin Exp Nephrol. 2017 Jun;21(3):523. PubMed PMID: 27389681; PubMed Central PMCID: PMC5486467.
Yaguchi A, Yonekubo S, Maruyama I, Tatemichi S, Maruyama K, Kobayashi M. Comparison of Phosphate Binding Capacities of PA21, A Novel Phosphate Binder, with those of other Phosphate Binders in vitro and in vivo. Drug Res (Stuttg). 2016 May;66(5):262-9. doi: 10.1055/s-0035-1569328. Epub 2016 Jan 13. PubMed PMID: 26761712.
Yaguchi A, Tatemichi S, Takeda H, Kobayashi M. PA21, a novel phosphate binder, improves renal osteodystrophy in rats with chronic renal failure. PLoS One. 2017 Jul 13;12(7):e0180430. doi: 10.1371/journal.pone.0180430. eCollection 2017. PubMed PMID: 28704404; PubMed Central PMCID: PMC5509238.